Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.28) per share for the quarter.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same quarter last year, the business earned ($1.00) EPS. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eledon Pharmaceuticals Stock Performance

Shares of NASDAQ ELDN traded down $0.08 during trading on Tuesday, hitting $3.03. The company had a trading volume of 17,660 shares, compared to its average volume of 283,628. Eledon Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $5.54. The business's 50-day moving average is $3.35 and its 200 day moving average is $3.99. The company has a market cap of $181.14 million, a P/E ratio of -1.50 and a beta of 0.08.

Wall Street Analysts Forecast Growth

Separately, Guggenheim started coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a "buy" rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).